Back to All Events

Pulmonary-Allergy Drugs Advisory Committee

  • IQVIA Solutions Denmark A/S Denmark (map)

The USFDA has scheduled a Pulmonary-Allergy Drug Advisory Committee [PADAC] on November 17, 2023, to discuss a new drug application (NDA-215010), for gefapixant oral tablets, submitted by Merck Sharp & Dohme Corp., for the proposed indication of treatment of adults with refractory or unexplained chronic cough.

Source:: https://www.fda.gov/advisory-committees/advisory-committee-calendar/november-17-2023-meeting-pulmonary-allergy-drugs-advisory-committee-11172023
Earlier Event: November 16
Oncologic Drugs Advisory Committee
Later Event: March 5
Medical Imaging Drugs Advisory Committee